TG Therapeutics (0VGI) Income Statement
TG Therapeutics Income Statement
Last quarter (Q2 2026), TG Therapeutics's total revenue was $240.34M, an increase of 70.27% from the same quarter last year. In Q2, TG Therapeutics's net income was $7.78M. See TG Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 616.29M | $ 329.00M | $ 233.66M | $ 2.79M | $ 6.69M | |
| $ 515.57M | $ 290.52M | $ 219.53M | $ 2.52M | $ 5.90M | |
| $ 392.25M | $ 248.59M | $ 198.90M | $ 220.84M | $ 350.67M | |
| Depreciation and Amortization | $ 244.00K | $ 280.00K | $ 423.00K | $ 515.00K | $ 494.00K |
| $ 134.36M | $ 49.90M | $ 26.10M | $ -213.11M | $ -341.97M | |
| $ 123.32M | $ 41.93M | $ 20.63M | $ -218.32M | $ -344.77M | |
| $ -15.93M | $ -16.34M | $ -7.57M | $ -5.50M | $ -3.33M | |
| $ 107.39M | $ 25.59M | $ 13.06M | $ -223.81M | $ -348.10M | |
| $ 447.18M | $ 23.38M | $ 12.67M | $ -223.81M | $ -348.10M | |
| Per Share Metrics | |||||
| Basic EPS | $ 3.10 | $ 0.16 | $ 0.09 | $ -1.46 | $ -2.63 |
| Diluted EPS | $ 2.77 | $ 0.15 | $ 0.09 | $ -1.46 | $ -2.63 |
| Weighted Average Shares Outstanding | 144.32M | 145.32M | 141.96M | 135.41M | 132.22M |
| Weighted Average Shares Outstanding (Diluted) | 161.41M | 160.34M | 148.51M | 135.41M | 132.22M |
Currency in USD
